Table 1.
Cohort 1 (Early Effects Study): Baseline Characteristics in Groups Treated With Different Chemotherapy Strategies
| Surveillance (n = 10) | 1 to 2 Cycles of BEP Low-Intensity Cisplatin (n = 7) | 3 to 4 Cycles of BEP High-Intensity Cisplatin (n = 10) | |
|---|---|---|---|
| Age, yrs | 39 ± 3 | 31 ± 2 | 34 ± 2 |
| Height, m | 1.79 ± 0.02 | 1.78 ± 0.03 | 1.77 ± 0.03 |
| Weight, kg | 93.5 ± 7.0 | 90.4 ± 5.8 | 88.7 ± 3.8 |
| Body mass index, kg/m2 | 28.9 ± 2.0 | 28.3 ± 1.4 | 28.3 ± 1.1 |
| Systolic blood pressure, mm Hg | 122.9 ± 5.3 | 134.1 ± 3.4 | 131.7 ± 4.3 |
| Diastolic blood pressure, mm Hg | 73.1 ± 4.2 | 76.7 ± 2.9 | 79.0 ± 3.0 |
| Heart rate, beats/min | 66.7 ± 3.0 | 70.9 ± 5.3 | 64.7 ± 2.8 |
| Cholesterol, mmol/l | 5.2 ± 0.3 | 5.1 ± 0.5 | 5.5 ± 0.2 |
| Triglycerides, mmol/l | 1.2 ± 0.2 | 1.1 ± 0.2 | 1.9 ± 0.5 |
| LDL cholesterol, mmol/l | 3.3 ± 0.3 | 3.4 ± 0.4 | 3.5 ± 0.2 |
| HDL cholesterol, mmol/l | 1.2 ± 0.1 | 1.3 ± 0.1 | 1.8 ± 0.4 |
| Glucose, mmol/l | 4.9 ± 0.1 | 5.1 ± 0.2 | 5.0 ± 0.2 |
| HbA1c, mmol/mol | 34.7 ± 1.1 | 33.1 ± 1.0 | 35.5 ± 1.2 |
| vWF:Ag, % | 44.3 ± 4.8 | 38.4 ± 3.4 | 45.2 ± 2.8 |
| Log urine ACR, mg/l | −0.18 ± 0.10 | −0.23 ± 0.08 | −0.14 ± 0.05 |
| Histological diagnosis | |||
| Seminoma | 7 (70) | — | 2 (20) |
| Nonseminoma/mixed | 3 (30) | 7 (100) | 8 (80) |
| Performance status | |||
| 0 | 10 (100) | 7 (100) | 6 (60) |
| 1 | — | — | 4 (40) |
| Medical history | |||
| Hypertension | 1 (10) | — | 1 (10) |
| Diabetes | - | — | — |
| Smoker | 1 (10) | — | — |
| Medications | |||
| Alpha-blocker | — | — | 1 (10) |
| Angiotensin-II receptor blocker | — | — | 1 (10) |
Values are mean ± SEM or n (%). Units reported in mmol/l can be converted to mg/dl through the following conversion factors: cholesterol mmol/l = mg/dl ÷ 38.6; triglyceride mmol/l = mg/dl ÷ 88.5; Glucose mmol/l = mg/dl ÷ 18.
ACR = albumin to creatinine ratio; BEP = bleomycin, etoposide, and cisplatin; HDL = high-density lipoprotein; LDL = low-density lipoprotein; vWF:Ag = von Willebrand factor antigen.